AllianceBernstein
QNCX icon

AllianceBernstein’s Quince Therapeutics QNCX Stock Holding History

AllianceBernstein’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-152
Closed -$188K – 3355
2022
Q1 		$188K Hold
152
– – ﹤0.01% 3005
2021
Q4 		$384K Hold
152
– – ﹤0.01% 2847
2021
Q3 		$2.79M Hold
152
– – ﹤0.01% 1961
2021
Q2 		$1.61M Buy
152
+98
+181% +$822K ﹤0.01% 2307
2021
Q1 		$389K Sell
54
-32
-37% -$230K ﹤0.01% 2786
2020
Q4 		$478K Sell
86
-11
-11% -$97.5K ﹤0.01% 2618
2020
Q3 		$970K Sell
97
-3
-3% -$27.3K ﹤0.01% 2200
2020
Q2 		$926K Buy
100
+26
+35% +$238K ﹤0.01% 2244
2020
Q1 		$670K Sell
74
-4
-5% -$39.5K ﹤0.01% 2218
2019
Q4 		$876K Buy
78
+32
+70% +$193K ﹤0.01% 2331
2019
Q3 		$229K Buy
+46
New +$283K ﹤0.01% 2897

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

AllianceBernstein's QNCX Position: Q2 2022 in Review

AllianceBernstein sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 152 shares — an estimated $188K sold.

AllianceBernstein first reported a position in QNCX in Q3 2019 and held it in 11 quarters. The position peaked at $2.79M in Q3 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

  • AllianceBernstein reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
  • AllianceBernstein sold 152 Quince Therapeutics shares in Q2 2022, an estimated $188K.
  • AllianceBernstein first reported a position in Quince Therapeutics in Q3 2019 and held it in 11 quarters.
  • AllianceBernstein's Quince Therapeutics position peaked at $2.79M in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.